Minghui Pharmaceutical Reports Topline Data from P-III Study of Tofacitinib Etocomil (MH004) Ointment for Atopic Dermatitis
Shots:
- The P-III study assessed the safety & efficacy of tofacitinib etocomil ointment 1.0% (BID, pan-Jak inhibitor) vs vehicle to treat patients (n=377; ≥12yrs.) with mild to moderate atopic dermatitis (AD) for 8wks., followed by 44wks. OLE for long-term safety
- Study reached its 1EPs, depicting 41.0% vs 10.3% of participants achieving IGA-TS and 58.2% vs 19.8% of them achieving EASI-75 at wk.4
- The 2EPs were also achieved, showing improvements in IGA-TS, EASI-75 and NRS4 score at wk.8. Tofacitinib etocomil was well-tolerated, with mild to moderate TRAEs and no drug-related SAEs
Ref: PR Newswire | Image: Minghui Pharmaceutical
Related News:- Minghui Pharmaceutical Reports Initial Data from P-I Study of MHB039A for R/R Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
